BRAF and thyroid gland undifferentiated (anaplastic) carcinoma: The combination of B-Rapidly Accelerated Fibrosarcoma (BRAF) and mitogen-activated protein kinase kinase (MEK) inhibitors is also being explored for BRAF V600E-mutated anaplastic thyroid carcinoma [101,102].